Friends of Cancer Research Virtual Meeting
A Path for Early Detection:
How Real-World Evidence Can Support Regulatory Decision-Making for Multi-Cancer Early Detection Screening Tests
Thank you to all that attended!
Click the Link Below to Watch the Full Meeting:
https://youtu.be/J_G0C7vN724
Click HERE to access the Meeting White Paper.
Tuesday, March 29, 2022
12:00PM EDT – 1:00PM EDT
Friends of Cancer Research (Friends) is proud to announce a new virtual meeting, A Path for Early Detection: How Real-World Evidence Can Support Regulatory Decision-Making for Multi-Cancer Early Detection Screening Tests.
Despite many advances in oncology care, many cancers lack effective early detection tools and thus continue to be diagnosed at later stages leading to a higher burden of care and potentially worse outcomes. Recent innovations have enabled the development of technologies that can detect the presence of multiple types of cancer from a liquid biopsy, termed multi-cancer early detection (MCED) screening tests, which may aid in detecting cancers earlier. Given the novel nature of MCED screening tests and unique feasibility challenges associated with generating evidence through traditional clinical screening trials, there is an opportunity to explore innovative approaches for generating and assessing evidence that can help robustly characterize the safety and effectiveness of MCED screening tests.
This meeting will discuss opportunities and considerations for use of real-world data (RWD) to supplement evidence generation for MCED screening tests for regulatory decision-making and provide insight into future opportunities for use of MCED screening in oncology drug development.
Register for the meeting above and stay tuned for updates announcing speakers and panels.
Final Agenda
12:00 – Welcome & Introductions
12:02 – 12:06pm – Opening Keynote
- Dr. Ned Sharpless, Director, National Cancer Institute
12:06pm – Panel 1 – RWD to Supplement Regulatory Decision-Making
- Moderator: Daniel F. Hayes, University of Michigan Rogel Cancer Center
- Ruth Etzioni, University of Washington and the Fred Hutchinson Cancer Research Center
- Girish Putcha, Freenome
- Sam Roosz, Crescendo Health
- Wendy Rubinstein, U.S. FDA CDRH
- Seema Singh, Exact Sciences Corporation
12:34pm – Panel 2 – Looking Ahead: Implications of MCED Screening Tests on Oncology Drug Development
- Moderator: Ernest Hawk, The University of Texas MD Anderson Cancer Center
- Nicole Drezner, U.S. FDA CDER
- Dina Gifkins, Johnson & Johnson
- Jody Hoyos, Prevent Cancer Foundation
- Joshua Ofman, GRAIL
- Nickolas Papadopoulos, Johns Hopkins University
12:58pm – Closing Remarks
